Daniel Pinto1, Shyam Prabhakaran2, Elizabeth Tipton3, Andrew M Naidech4. 1. Marquette University, Minneapolis, Minnesota. 2. University of Chicago, Chicago, Illinois. 3. Northwestern University, Evanston, Illinois. 4. Northwestern University at Chicago, Chicago, Illinois. Electronic address: a-naidech@northwestern.edu.
Abstract
BACKGROUND: Seizures are a morbid complication of intracerebral hemorrhage (ICH) and increase the risk for herniation, status epilepticus, and worse patient outcomes. Prophylactic levetiracetam is administered to approximately 40% of patients with ICH. It is unclear which patients are consciously selected for treatment by physicians. We sought to determine how patients are selected for treatment with prophylactic levetiracetam after ICH. METHODS: We administered an adaptive conjoint analysis using decision making software to an NIH Stroke Trials Network Working Group. The adaptive conjoint analysis determines the most influential attributes for making a decision in an iterative, algorithm-driven process. We asked respondents which would most influence a decision to administer prophylactic levetiracetam. The attributes and their levels were taken from published phenotypes associated with prophylactic seizure medications and the likelihood of seizures after ICH: hematoma location (lobar or basal ganglia), hematoma volume (<=10 mL or >10 mL), level of consciousness (Glasgow Coma Scale 5-12 or Glasgow Coma Scale 13-15), age (<65 or ≥65 years), and race (White or Caucasian or Black/African American). The algorithm terminated when the attributes were ranked from most to least influential. RESULTS: The study sample included 27 respondents who completed the adaptive conjoint analysis out of 42 who responded to the survey with a mean age of 43.4 ± 9.4 years. The attribute with the greatest weight was hematoma location (30%), followed by reduced level of consciousness (24%), hematoma volume (19%), race (14%), and age (13%). Ranks of attributes were different (P < .001). CONCLUSIONS: The decision to administer prophylactic levetiracetam to patients with ICH is driven by lobar hematoma location and depressed level of consciousness. Future research on prophylactic seizure medication could focus on patients most likely to receive it.
BACKGROUND:Seizures are a morbid complication of intracerebral hemorrhage (ICH) and increase the risk for herniation, status epilepticus, and worse patient outcomes. Prophylactic levetiracetam is administered to approximately 40% of patients with ICH. It is unclear which patients are consciously selected for treatment by physicians. We sought to determine how patients are selected for treatment with prophylactic levetiracetam after ICH. METHODS: We administered an adaptive conjoint analysis using decision making software to an NIH Stroke Trials Network Working Group. The adaptive conjoint analysis determines the most influential attributes for making a decision in an iterative, algorithm-driven process. We asked respondents which would most influence a decision to administer prophylactic levetiracetam. The attributes and their levels were taken from published phenotypes associated with prophylactic seizure medications and the likelihood of seizures after ICH: hematoma location (lobar or basal ganglia), hematoma volume (<=10 mL or >10 mL), level of consciousness (Glasgow Coma Scale 5-12 or Glasgow Coma Scale 13-15), age (<65 or ≥65 years), and race (White or Caucasian or Black/African American). The algorithm terminated when the attributes were ranked from most to least influential. RESULTS: The study sample included 27 respondents who completed the adaptive conjoint analysis out of 42 who responded to the survey with a mean age of 43.4 ± 9.4 years. The attribute with the greatest weight was hematoma location (30%), followed by reduced level of consciousness (24%), hematoma volume (19%), race (14%), and age (13%). Ranks of attributes were different (P < .001). CONCLUSIONS: The decision to administer prophylactic levetiracetam to patients with ICH is driven by lobar hematoma location and depressed level of consciousness. Future research on prophylactic seizure medication could focus on patients most likely to receive it.
Authors: Kevin N Sheth; Sharyl R Martini; Charles J Moomaw; Sebastian Koch; Mitchell S V Elkind; Gene Sung; Steven J Kittner; Michael Frankel; Jonathan Rosand; Carl D Langefeld; Mary E Comeau; Salina P Waddy; Jennifer Osborne; Daniel Woo Journal: Stroke Date: 2015-10-15 Impact factor: 7.914
Authors: Andrew M Naidech; Jennifer Beaumont; Kathryn Muldoon; Eric M Liotta; Matthew B Maas; Matthew B Potts; Babak S Jahromi; David Cella; Shyam Prabhakaran; Jane L Holl Journal: Crit Care Med Date: 2018-09 Impact factor: 7.598
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: Lisa J Rosenthal; Brandon A Francis; Jennifer L Beaumont; David Cella; Michael D Berman; Matthew B Maas; Eric M Liotta; Robert Askew; Andrew M Naidech Journal: Psychosomatics Date: 2016-08-05 Impact factor: 2.386
Authors: Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello Journal: Stroke Date: 2007-05-03 Impact factor: 7.914
Authors: Elena Haapaniemi; Daniel Strbian; Costanza Rossi; Jukka Putaala; Tuulia Sipi; Satu Mustanoja; Tiina Sairanen; Sami Curtze; Jarno Satopää; Reina Roivainen; Markku Kaste; Charlotte Cordonnier; Turgut Tatlisumak; Atte Meretoja Journal: Stroke Date: 2014-05-29 Impact factor: 7.914
Authors: Steven R Messé; Lauren H Sansing; Brett L Cucchiara; Susan T Herman; Patrick D Lyden; Scott E Kasner Journal: Neurocrit Care Date: 2009-03-25 Impact factor: 3.210
Authors: Aaron F Struck; Berk Ustun; Andres Rodriguez Ruiz; Jong Woo Lee; Suzette M LaRoche; Lawrence J Hirsch; Emily J Gilmore; Jan Vlachy; Hiba Arif Haider; Cynthia Rudin; M Brandon Westover Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Andrew M Naidech; Rajeev K Garg; Storm Liebling; Kimberly Levasseur; Micheal P Macken; Stephan U Schuele; H Hunt Batjer Journal: Stroke Date: 2009-09-24 Impact factor: 7.914
Authors: Ava L Liberman; Daniel Pinto; Sara K Rostanski; Daniel L Labovitz; Andrew M Naidech; Shyam Prabhakaran Journal: Neurohospitalist Date: 2018-09-13
Authors: Henrique Lopes; Ricardo Baptista-Leite; Diogo Franco; Miguel A Serra; Amparo Escudero; José M Martín-Moreno Journal: Front Public Health Date: 2022-01-07
Authors: Andrew M Naidech; Bradley Weaver; Matthew Maas; Thomas P Bleck; Stephen VanHaerents; Stephan U Schuele Journal: Crit Care Med Date: 2021-06-01 Impact factor: 9.296